enGene Q3 2026 net loss $32.5M; cash $266.3M; BLA filing on track for 4Q 2026

enGene Therapeutics Inc.

Net loss $32.5M ($0.47/share) vs $29.0M ($0.57/share) year ago; cash $266.3M.
Total opex $34.0M vs $29.9M; R&D down $2.5M, G&A up $6.6M.
Pivotal Cohort 1 data update, pre-BLA FDA meeting, and BLA initiation all planned for 4Q 2026.
Surfactant cohort safety run-in cleared; KOL webinar on Oct 15, 2026.
Michael Heffernan became Chairman in July 2026, succeeding Richard Glickman.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.